2025 annual financial data
Avalo Therapeutics 2025 Operating margin
Direct answer
Operating margin was -123,601.69%.
Operating income was -72,925,000 USD and net income was -78,259,000 USD.
Operating cash flow was -51,458,000 USD.
Get free Avalo Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 59,000 USD
- Operating income
- -72,925,000 USD
- Net income
- -78,259,000 USD
- Operating cash flow
- -51,458,000 USD